May is almost over, but we still owe you biotech hires news from the month of April, in which we didn’t see too much activity at the big pharmas, but saw plenty of executive movement at small and midsized biotechs.

五月即将结束，但我们仍然欠你四月份的生物技术招聘消息，在那个月我们没有看到大型制药公司有太多活动，但中小型生物技术公司却有很多高管变动。

Read on for the highlights.

继续阅读以了解重点。

New CEO takes helm at Cue.

新任首席执行官接管Cue。

Cue Biopharma appointed

Cue Biopharma 任命

Dr Shao‑Lee Lin

邵丽琳博士

as chief executive officer. An immunology‑focused physician‑scientist and seasoned biopharmaceutical executive, Dr Lin brings more than 25 years of leadership experience to the Boston‑based clinical‑stage biopharma, which is developing novel T-cell biologics. Her career has been marked by scaling companies from inception to IPO and building multi‑billion‑dollar therapeutic portfolios, including her role as founder and CEO of ACELYRIN..

作为首席执行官。林博士是一位专注于免疫学的医生科学家，同时也是经验丰富的生物制药高管，她为这家位于波士顿的临床阶段生物制药公司带来了超过25年的领导经验，该公司正在开发新型T细胞生物制品。她的职业生涯以将公司从创立扩展到首次公开募股（IPO）以及构建价值数十亿美元的治疗产品组合为标志，其中包括她作为创始人兼首席执行官在ACELYRIN的任职经历。

Orano Med taps experienced leader.

奥拉诺医学公司聘请了经验丰富的领导者。

At Orano Med,

在奥拉诺医学，

Frederic Desdouits

弗雷德里克·德杜伊特

was named CEO. Desdouits previously served as CEO of TreeFrog Therapeutics, a French biotech specialising in stem cell‑based therapies. Earlier, he led pharmaceutical activities at Seqens, a global leader in specialty ingredient manufacturing, and oversaw business development and US pharmaceutical operations at Pierre Fabre.

被任命为首席执行官。德斯杜伊特曾担任法国生物技术公司TreeFrog Therapeutics的首席执行官，该公司专注于基于干细胞的疗法。更早之前，他领导了全球特种成分制造的领导者Seqens的制药业务，并负责皮尔法伯的业务发展和美国制药运营。

Orano Med is a clinical‑stage biotechnology company developing novel targeted cancer therapies..

Orano Med 是一家临床阶段的生物技术公司，致力于开发新型靶向癌症疗法。

Paratus Sciences builds out its executive and clinical leadership

帕拉图斯科学公司扩充其执行和临床领导团队

. Paratus Sciences, a Boston‑ and Singapore‑based biotech integrating evolutionary biology, AI‑powered discovery, and deep multi-omic data for drug discovery, made several appointments.

总部位于波士顿和新加坡的生物技术公司 Paratus Sciences 致力于将进化生物学、人工智能驱动的发现和深度多组学数据整合用于药物研发，并进行了多项任命。

Alicia Secor

阿丽西亚·塞科尔

stepped up as president and CEO. Secor most recently held the same roles at Atalanta Therapeutics and previously served as President and CEO of Juniper Pharmaceuticals until its acquisition by Catalent.

接任总裁兼首席执行官。塞科尔最近在阿塔兰塔治疗公司担任同样的职务，此前曾任朱尼珀制药公司总裁兼首席执行官，直到该公司被卡泰伦特收购。

The company also strengthened its clinical leadership with the appointment of

公司还通过任命加强了其临床领导能力

Ganesh Mugundu

甘内什·穆贡杜

as iVP and head of clinical development. Mugundu most recently served as VP and head of early clinical development at Astria Therapeutics, where he led scientific strategy and execution across immunologic and allergic disease programmes and was a member of the senior leadership team. His earlier career has included leadership roles at Takeda, AstraZeneca, and Pfizer..

作为iVP和临床开发主管。Mugundu最近曾担任Astria Therapeutics的副总裁和早期临床开发主管，他在那里领导了免疫和过敏性疾病项目的科学战略和执行，并且是高级领导团队的一员。他之前的职业生涯包括在武田、阿斯利康和辉瑞担任领导职务。

Completing the trio of senior appointments, Paratus named

完成这一高级任命的三人组，帕拉图斯命名了

Jeffrey Young

杰弗里·杨

as CFO. Young previously served as CFO at Atalanta Therapeutics, where he played an instrumental role in the company’s $97 million Series B financing.

作为首席财务官。杨之前在阿塔兰塔治疗公司担任首席财务官，在该公司9700万美元的B轮融资中发挥了重要作用。

LEO Pharma strengthens UK leadership

利奥制药加强英国领导力

. Danish dermatology specialist LEO Pharma appointed

丹麦皮肤病学专家LEO制药公司任命

Matt Ferriday

马特·费里迪

as general manager for the UK. Ferriday joined from Ipsen Biopharma, where he held senior leadership roles spanning rare diseases and neuroscience.

作为英国总经理。费里戴从益普生生物制药公司加入，他在罕见病和神经科学领域担任过多项高级领导职务。

Finance chiefs step into key biopharma and biotech roles.

财务主管在关键的生物制药和生物技术领域担任重要角色。

A handful of organisations named new CFOs in April.

四月，有少数机构任命了新的首席财务官。

Halozyme appointed

Halozyme 任命

Darren Snellgrove

达伦·斯内尔格罗夫

as chief financial officer. Snellgrove most recently led investor relations at Johnson & Johnson and previously served as CFO of J&J’s pharmaceutical business. Halozyme is advancing disruptive solutions aimed at improving patient experiences and outcomes for emerging and established therapies.

作为首席财务官。斯内尔格罗夫最近领导了强生公司的投资者关系部门，并曾担任强生制药业务的首席财务官。Halozyme 正在推进颠覆性解决方案，旨在改善新兴和现有疗法的患者体验和治疗效果。

At MinervaX,

在米涅尔瓦X，

Hans Henrik Chrois Christensen

汉斯·亨里克·克罗伊斯·克里斯滕森

was appointed CFO. Christensen brought more than two decades of financial leadership experience across private and public life sciences companies, including responsibility for financing strategies, M&A transactions, and organisational scale‑up. MinervaX is developing a prophylactic vaccine against Group B Streptococcus based on research from Lund University..

被任命为首席财务官。克里斯滕森带来了超过二十年的私营和公营生命科学公司的财务领导经验，包括负责融资策略、并购交易和组织规模扩大。米涅尔瓦克斯公司正在开发一种基于隆德大学研究的预防B群链球菌的疫苗。

Boston‑based Strand Therapeutics named

总部位于波士顿的Strand Therapeutics公司命名为

Kunal Bhatia

库纳尔·巴蒂亚

into the top finance role. Bhatia joined the programmable mRNA therapy company with a 15‑year background in investment banking, having advised more than 100 public and private biopharmaceutical companies on financing and business development.

进入最高财务职位。巴蒂亚加入了可编程 mRNA 疗法公司，拥有 15 年的投资银行背景，曾为 100 多家公有和私有生物制药公司提供融资和业务发展方面的建议。

Biotechs add scientific, medical leaders.

生物技术公司增加了科学和医学领域的领导者。

April saw a smattering of chief medical officers and chief scientific officers appointed at biotechs working on novel therapies.

四月，一些生物技术公司任命了首席医疗官和首席科学官，这些公司正在研发新型疗法。

Asgard Therapeutics appointed

阿斯加德治疗公司任命

Dr Wolfram Brugger

沃尔夫拉姆·布吕格博士

as CMO. Brugger joined from NASDAQ‑listed Autolus Therapeutics, where he led the global clinical development programme for AUTO1, an autologous CD19 CAR-T therapy. Asgard is a privately held Swedish biotech pioneering

作为首席医学官。布吕格从纳斯达克上市的Autolus Therapeutics加入，他在那里领导了AUTO1的全球临床开发计划，AUTO1是一种自体CD19 CAR-T疗法。阿斯加德是一家私营的瑞典生物技术公司，致力于开创性研究。

in vivo

体内

direct cell reprogramming for cancer immunotherapy.

用于癌症免疫治疗的直接细胞重编程。

At Immunic, a late‑stage biotech developing novel oral therapies for neurologic diseases,

在Immunic，一家专注于开发神经系统疾病新型口服疗法的晚期生物技术公司，

Dr Michael Panzara

潘扎拉·迈克尔博士

was named chief medical officer. Panzara brings more than 25 years of experience advancing blockbuster multiple sclerosis therapies, guiding drugs from late‑stage development through global regulatory approvals.

被任命为首席医疗官。潘扎拉在推动重磅多发性硬化症疗法方面拥有超过25年的经验，指导药物从后期开发到全球监管审批。

Richard Sainson

理查德·塞恩森

joined Laigo Bio, early‑stage biotech based in the Netherlands as chief scientific officer, bringing more than 25 years of experience in oncology and immunology translational science and drug discovery.

加入位于荷兰的早期生物技术公司Laigo Bio，担任首席科学官，拥有超过25年的肿瘤学和免疫学转化科学及药物发现经验。

Enodia Therapeutics named

恩诺迪亚治疗公司命名

Dr Yvonne McGrath

伊冯·麦格拉思博士

to the CSO post. Prior to joining Enodia, McGrath served as CSO of iTeos Therapeutics, where she led discovery scientists and provided translational leadership to advance immuno‑oncology therapies into clinical development. Enodia is focused on developing small‑molecule therapies that enable degradation of disease‑driving proteins at the point of synthesis..

在加入Enodia之前，麦格拉思曾担任iTeos Therapeutics的首席科学官（CSO），她在该公司领导了发现科学家团队，并提供了转化科学方面的指导，推动免疫肿瘤学疗法进入临床开发阶段。Enodia专注于开发小分子疗法，旨在通过降解合成过程中的致病蛋白来治疗疾病。

UK‑based gene therapy firm EpilepsyGTx appointed

总部位于英国的基因治疗公司EpilepsyGTx任命

Dimitri Kullman

迪米特里·库尔曼

as chief scientific officer. Kullman is an internationally recognised leader in neuroscience with more than three decades of pioneering research into synaptic function; his work underpinned the creation of the company in 2021.

作为首席科学官。库尔曼是国际公认的神经科学领域领导者，在突触功能方面有三十多年的开创性研究；他的工作为公司在2021年的创立奠定了基础。

Two pharmas tap big pharma vets for medical affairs leadership.

两家制药公司聘请大型制药公司的资深人士担任医学事务领导职务。

Madrigal Pharmaceuticals appointed

马德里加尔制药公司任命

Dr Ricardo Rocha

里卡多·罗查博士

as EVP and global head of medical affairs. Rocha joined from Intellia Therapeutics and previously spent nearly 20 years at Novartis in leadership roles of increasing responsibility. Madrigal is focused on delivering novel therapeutics for metabolic dysfunction‑associated steatohepatitis (MASH). Meanwhile, Helus Pharma, a clinical‑stage pharma company developing novel serotonergic agonists, named .

作为执行副总裁和全球医学事务主管。罗查之前在英特利亚治疗公司工作，此前在诺华公司担任领导职务近20年，职责不断增加。马德里加尔专注于为代谢功能障碍相关的脂肪性肝炎（MASH）提供新型治疗方法。同时，处于临床阶段的制药公司赫勒斯制药，正在开发新型血清素能激动剂，任命了新的负责人。

Ken Kramer

肯·克莱默

as SVP medical affairs. At Karuna Therapeutics, Kramer served as VP and head of medical affairs, building medical capabilities during a period of significant organisational growth and supporting the company through its acquisition. Earlier, he spent more than a decade leading US psychiatry medical affairs teams at AbbVie and predecessor organisations..

作为高级副总裁医疗事务。在Karuna Therapeutics，Kramer担任副总裁和医疗事务主管，在组织显著增长期间建立了医疗能力，并在公司被收购过程中提供支持。更早之前，他在AbbVie及其前身机构领导美国精神病学医疗事务团队超过十年。

Stockholm biotech adds project manager.

斯德哥尔摩生物技术公司新增项目经理。

Pharmability, a Stockholm‑based biotech developing next‑generation treatments for autoimmune skin diseases, appointed

总部位于斯德哥尔摩的生物技术公司 Pharmability 正在开发用于自身免疫性皮肤病的下一代治疗方法，任命了新的负责人。

Agneta Wennerholm

阿格尼塔·温内霍尔姆

as consulting clinical project manager. Wennerholm brings more than 25 years of experience across pharmaceutical and biotechnology companies and clinical CROs, spanning a broad range of therapeutic areas.

担任咨询临床项目经理。温内霍姆在制药和生物技术公司以及临床CRO方面拥有超过25年的经验，横跨广泛的治疗领域。

European biotechs add development pros.

欧洲生物技术公司增加开发专家。

MinervaX further expanded its leadership team with the appointment of

MinervaX通过任命进一步扩大了其领导团队

Jamila Louahed

贾米拉·卢阿赫德

as chief development officer. Louahed joined from GSK, where she held a senior leadership role in vaccine research and development. And at clinical-stage retinal gene therapy company AAVantgarde,

作为首席开发官。Louahed曾在GSK任职，她在疫苗研发领域担任过高级领导职务。而在临床阶段的视网膜基因治疗公司AAVantgarde，

Philip Lao

老菲利普

came aboard as VP business development. Lao previously served as head of BD at Adverum Biotechnologies, where he led the company’s sale to Eli Lilly in December 2025. His career before that included extensive M&A and strategic licensing experience at Novartis, Pfizer, and Takeda.

担任业务发展副总裁。Lao 此前曾担任 Adverum 生物技术公司业务发展主管，并于 2025 年 12 月领导了该公司出售给礼来公司的事宜。在那之前，他的职业生涯包括在诺华、辉瑞和武田制药的广泛并购和战略许可经验。

Legal and operational leadership strengthened at Structure Therapeutics.

结构治疗公司加强了法律和运营领导力。

Structure Therapeutics appointed

结构治疗公司任命

Matthew Lang

马修·朗

as general counsel and chief operating officer. Lang most recently served as chief legal officer and secretary at Metsera, helping to guide the company through its $10 billion acquisition by Pfizer. Structure Therapeutics is a clinical‑stage biopharmaceutical company developing innovative oral small‑molecule treatments for chronic metabolic conditions with significant unmet need..

作为总法律顾问兼首席运营官。朗最近担任 Metsera 的首席法律官兼秘书，帮助引导公司完成辉瑞以 100 亿美元收购的交易。Structure Therapeutics 是一家临床阶段的生物制药公司，致力于开发创新的口服小分子治疗药物，针对存在显著未满足需求的慢性代谢疾病。

That’s it for our

我们的到此为止

pharma and biotech hires

制药和生物技术招聘

this month, but stay tuned for our other hires round-ups and remember, you can send your own hires to

本月，但请继续关注我们的其他招聘汇总，记住，您可以将自己的招聘发送到

editorial@pharmaphorum.com

编辑部@药坛.com

for inclusion in this column.

列入本专栏。